- Home
- AURA
as 11-15-2024 4:00pm EST
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its lead candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 572.0M | IPO Year: | 2021 |
| Target Price: | $23.00 | AVG Volume (30 days): | 184.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.72 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.63 - $12.38 | Next Earning Date: | 11-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Aura Biosciences Inc. (AURA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Elazzouzi Amy | AURA | Vice President, Finance | Oct 29 '24 | Sell | $10.74 | 553 | $5,938.39 | 39,443 | |
| de los Pinos Elisabet | AURA | See Remarks | Oct 18 '24 | Sell | $12.04 | 24,992 | $300,838.70 | 329,847 | |
| Feder Julie B | AURA | Chief Financial Officer | Oct 18 '24 | Sell | $12.03 | 25,131 | $302,361.11 | 134,276 |
Latest Aura Biosciences Inc. News
AURA Breaking Stock News: Dive into AURA Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
Aura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights
Simply Wall St.
17 days ago
One Aura Biosciences Insider Raised Stake By 232% In Previous Year
MT Newswires
a month ago
Aura Biosciences Insider Sold Shares Worth $300,839, According to a Recent SEC Filing
GlobeNewswire
a month ago
Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial
Simply Wall St.
a month ago
Aura Biosciences, Inc. (NASDAQ:AURA) is a favorite amongst institutional investors who own 58%
Zacks
2 months ago
Aura Stock Up as Lead Drug Shows Superior Efficacy in Eye Cancer Study
MT Newswires
2 months ago
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday
MT Newswires
2 months ago
Aura Biosciences' Eye Cancer Therapy Shows Promise in Mid-Stage Study -- Shares Rise Pre-Bell
Compare AURA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AURA Aura Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.